The advisory committee vote today is the key catalyst. A positive vote would likely lead to accelerated approval and significant stock upside; a negative vote would be a major setback. Monitor the vote outcome and FDA decision timeline.
Drug in focus
REPL drug pipeline →TUDRIQEV
● Neutral Named in this 8-K- Impact
- Phase
- Approved (Accelerated Approval)
- Time to market
- Already approved and commercially available in the U.S. since October 2026.
- Next catalyst
- None dated
What to watchTUDRIQEV is now a commercial-stage asset, so the focus shifts from regulatory binary to revenue execution. Watch the next quarterly earnings (likely late January 2027) for early sales figures, formulary adoption metrics, and the permanent J-code expected by April 2027. The confirmatory Phase 3 trial data timeline is the next major binary but has no announced readout date yet.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 30 $5.41entry
- T+1 · 4mo ago +107.02%α +106.32% · $11.20
- T+5 · 3mo ago +137.71%α +134.09% · $12.86
- T+20 · 3mo ago +188.35%α +184.39% · $15.60
- T+60 · 25d ago +111.83%α +109.37% · $11.46
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Replimune presented its BLA resubmission for RP1 (vusolimogene oderparepvec, TUDRIQEV) in combination with nivolumab to the FDA advisory committee for advanced melanoma. The IGNYTE Phase 2 data showed a 33.6% ORR (16.4% CR), median DOR of 24.8 months, and a 3-year OS rate of 47.8% with a manageable safety profile. The FDA's initial clinical review had already recommended accelerated approval, making today's advisory committee vote a pivotal catalyst for the stock.
Key Facts
- IGNYTE Phase 2 ORR: 33.6% (95% CI: 25.8, 42) with 16.4% complete response rate
- Median duration of response: 24.8 months (95% CI: 14.8, NE)
- 3-year overall survival rate: 47.8% (median OS 32.9 months)
- No treatment-related Grade 5 adverse events; mainly Grade 1-2 toxicities
- FDA clinical review (July 2025) recommended accelerated approval, citing substantial evidence of effectiveness
- Advisory committee meeting held July 30, 2026; outcome will influence FDA decision
Financial Impact
No financial data in filing; potential approval would be transformative for pre-revenue biotech with $454M market cap
Risk Factors
- Advisory committee may vote against approval despite positive FDA review
- FDA is not bound by committee vote and could still reject
- Confirmatory trial (IGNYTE-3) OS data not expected until 2030, leaving accelerated approval subject to post-market verification
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-088481 |
| Document: tm2621663d1_8k.htm | 0001104659-26-088481 |
| Document: 0001104659-26-088481-index-headers.html | 0001104659-26-088481 |
| Document: 0001104659-26-088481-index.html | 0001104659-26-088481 |
| Document: 0001104659-26-088481.txt | 0001104659-26-088481 |
Track record
32 reports on REPL
8 of 12 bullish or bearish reports moved the stock their way by T+60. Best: +75.56% at T+60 after the May 30, 2026 report. 12 of 13 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $21.90 Now $21.41 −2.24% settles Feb 12
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $21.78 Now $21.41 −1.70% settles Feb 9
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $23.28 Now $21.41 −8.03% settles Feb 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $23.28 Now $21.41 −8.03% settles Feb 8
- Nov 9, 20267d ago SC 13G/A Neutral 2/10 Entry $22.26 Now $21.41 −3.82% settles Feb 5
- Nov 6, 202610d ago 10-Q/A Neutral 3/10 Entry $22.26 Now $21.41 −3.82% settles Feb 5
- Nov 4, 202612d ago Institutional Cluster Bearish 4/10 Entry $20.69 Now $21.41 −3.48% settles Feb 2
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $20.69 Now $21.41 +3.48% settles Feb 2
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $20.65 Now $21.41 +3.68% settles Feb 1
- Oct 30, 202617d ago 144 Neutral 2/10 Entry $19.49 Now $21.41 +9.85% settles Jan 29
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers